The GMMMG high cost drugs pathways for rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis have been updated. The updates follow a technical review to add information on the MHRA safety alert for JAK inhibitors, and links to NICE TA861 for upadacitinib for treating active non-radiographic axial spondyloarthritis.
GMMMG high cost drugs pathways are available on the Clinical Guidance and Pathways page.